Post-Doctoral Fellow Position at Shanghai Institute of Materia Medica/Suzhou Xenofinder

中科院上海药物研究所和苏州锐迪欧公司招聘联合培养药物代谢博士后招聘简介

本药物代谢博士后培训旨在为新药研发企业培养急需的药物代谢高端人才，共招2人，博士后在站2-3年。欢迎具有机化学基础和高分辨质谱仪应用经验的中国、美国博士申请，录取者需要尽快开始博士后研究。

1. 专业介绍

药物生物转化 (Biotransformation)是药物代谢和药物动力学（DMPK）的一个重要分支，其研究内容主要是应用液相色谱-高分辨质谱联用（LC-HRMS）和放射性同位素检测技术发现、鉴定和定量分析体外和体内的代谢物。生物转化研究目的是揭示药物在体内的代谢清除途径、代谢物的毒性、药理作用和代谢酶介导的药物相互作用（DDI）机理等。代谢物鉴定（Met ID）涉及到新药研发全过程：从先导候选物代谢软位点分析到临床人体放射性ADME研究，所以大部分新药研发企业需要具有生物转化教育背景的高端人才。但是，由于多种原因，中国、美国很少有科研单位培养以Met ID为技术核心的药物生物转化博士和博士后。本药物代谢博士后培训和研究集中在新药的生物转化方面。

2.  应聘条件

• 获得DMPK、分析化学、药物分析、天然药物化学、药物化学或相关专业博士学位；
• 具有较好的有机化学基础和较丰富的应用高分辨质谱仪的经验；对DMPK学科和放射性同位素14C检测有一定的了解；
• 对在工业界从事新药DMPK研究有很大兴趣；具有独立科研和写作学术论文的能力和经验；
• 乐观开朗、积极向上、具有团队合作精神。

3. 研究方向研究方向

• 应用LC-HRMS和放射性14C开展Met ID和研究生物转化生成机理；
• 应用体外、体内Met ID实验模型和分析方法完成新药DMPK研发项目；
• 建立和发展新型药物（ADC、PDC、PROTAC等）ADME研究的新策略和新方法；
• 建立和发展各种非CYP代谢酶表型和酶动力学研究的模型和方法，并用于新药的研发；
• 协助课题组长申请基金、独立申请博士后基金和其他基金。

4.工作地点和待遇

按照项目要求，工作地点在上海或者苏州，博士后在站2-3年。按照中科院上海药物所相关规定提供与学历和经验相匹配的有竞争力的待遇；承担药企新药DMPK研发项目时，有绩效补贴。博士后出站后，推荐申请在中资或跨国药企开展与DMPK相关的工作。

5. 应聘方式

欢迎有志于在新药DMPK研发的中国、美国博士申请。应聘者请将个人简历发至：This email address is being protected from spambots. You need JavaScript enabled to view it.和This email address is being protected from spambots. You need JavaScript enabled to view it.。标题注明“药物代谢博士后”。应聘者Email中简述对岗位的理解、个人职业规划和期望待遇。对符合条件者尽快安排在ASMS会议期间面试或网上面试。ASMS会议上联系方式：微信Mingshe2014。 招聘单位对应聘资料严格保密。本招聘启事直到岗位招满前一直有效。

6. 中科院上海药物研究所刁星星课题组简介

中国科学院上海药物研究所药物代谢研究中心是专注于新药DMPK研究的教育、科研和项目服务的研究中心，其研究和服务范围涵盖药物的ADME、体外DDI和生物分析。中心拥有现有多位研究员（教授）和先进的DMPK研究仪器和设备。承担有973、863、国家自然科学基金等多项国家课题，与国内外100+ 家企业、20+ 家医院建立了合作关系。积累了300余种创新药物临床前和临床DMPK研究经验。

刁星星研究员团队有30余人，其中博士后3名、实验室主管4名，研究范围包括药物的生物转化、代谢酶表型、代谢物生成机理等。其实验室具有开展Met ID和放射性ADME实验的LC-HRMS和放射性检测仪器。先后为国内外20+家药企完成了30+项临床前和人体放射性ADME试验。

7. 苏州锐迪欧医药科技有限公司简介

苏州锐迪欧医药科技有限公司（简称“锐迪欧”）位于江苏省苏州市工业园区中科苏州药物研究院，是专注于开展创新药物Met ID和放射性ADME研究的服务平台。核心团队受过系统的药物代谢教育和训练，具有在美国和中国知名药企、CRO和科研机构开展新药研发的丰富经验，曾参与、主导或指导完成了多项支持小分子新药上市的ADME研究和各种新型药物的代谢研究。

锐迪欧从支持新药发现、开发和在中国及欧美日申报上市的角度，为全球新药研发企业提供以Met ID和放射性ADME研究为核心的代谢物鉴定一站式服务。服务范围涵盖从早期发现阶段的先导化合物优化、临床前候选新药的评估，到临床阶段的新药开发。锐迪欧具有完备的开展Met ID和放射性ADME实验的设备、能力和经验，能够开展各种新型药物的代谢研究，并可根据需要提供特殊的研究策略和针对性的解决方案。

8. 博士后导师简介

刁星星 研究员

Xingxing Diao received his PhD from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (Shanghai, China) in 2014 and completed his postdoctoral training in NIH (Baltimore, USA) in 2014-2016. He then worked in XenoBiotic Laboratories (Plainsboro, NJ, USA) and Celgene (Summit, NJ, USA) for 3 years prior to returning to China. In addition to leading XenoFinder, Dr. Diao is currently a professor at SIMM, where he established a comprehensive DMPK lab capable of conducting in vitro and in vivo metabolite profiling and identification, metabolizing enzyme phenotyping, animal PK, radiolabeled ADME studies in animals and human.

His PhD research focused on evaluating DMPK of 3-n-butylphthalide (NBP) in human, including human samples Met ID, quantification of NBP and 4 major metabolites, the metabolic bioactivation underlying the hepatotoxicity of NBP and the mechanism responsible for the isomer-selective distribution of 3-OH-NBP and 10-OH-NBP across blood-brain barrier.In NIH, he set up human hepatocyte incubation platform to study metabolism of new synthetic cannabinoid (SC) and developed strategies to analyze the use of new SCs for forensic investigation.In XenoBiotic Laboratories and Celgene, he conducted mainly biotransformation studies of new drug candidates, including metabolite profiling and identification using LC-HRMS and 14C-labeled ADME studies animals and human. In SIMM, Dr. Diao trains PhD candidates and postdocs, conducts mechanistic studies of drug biotransformation and investigative ADME research of new drug candidates. Dr. Diao published over 43 peer-reviewed research papers (29 papers are the first-author or corresponding author). (https://pubmed.ncbi.nlm.nih.gov/?term=Xingxing+Diao)

朱明社博士

Dr. Mingshe Zhu is an independent consultant to provide DMPK consultation services to biotech and pharma companies in China and USA (Mar 2017-present) in support of drug discovery, development, and regulatory submissions. He also served as the scientific advisor of DMPK Dept. at WuXi AppTec in Nanjing, China (Mar 2017-Dec 2021) with responsibilities of staff scientist training, developing new methods in ADME studies, technic marketing, key experimental design, data interpretation, and helping clients to solve program issues. He has involved in IND-enabling biotransformation and radiolabeled ADME studies in animals and human, which supported IND filing of many clinical candidates and NDA filings of over 10 drug candidates in China and USA, including the marketing approval of 5 new drugs (Anlotin, Ensartinib Hydrochloride, Fospropofol Disodium, Donafenib, Olverembatinib) in China.

Dr. Zhu previously worked in Dept. of Biotransformation, Bristol-Myers Squibb (BMS) for 19 years, where he and his team supported over 10 discovery programs, more than 15 development drug candidates, and the worldwide approvals of ABILIFY (Aripiprazole) and FORXIGA (Dapagliflozin). Dr. Zhu and his collaborators at BMS developed several innovative LC/MS workflows and data-mining technologies such as Mass Defect Filter, Background Subtraction and Multiple Reaction Monitoring for drug metabolite detection and identification, which are now routinely used in drug metabolism research worldwide. Recently, his research interests have been expanded to unconventional drug modalities, such as ADC, cyclic peptides, herbal medicines, covalent drugs, stable isotope labeled drugs, prodrugs, and protein therapeutics.

He received PhD in analytical toxicology at SUNY Albany and completed post-doctoral fellowship in drug metabolism at University of Washington. Dr. Zhu served the chair of ISSX focus group of “Bioanalysis in ADME Science” (2016-2018) and taught drug metabolism and mass spectrometry short courses at ASMS (2011-present), EAS (2002-2010) and ACS (2006, 2008). He co-edited two books, Drug Metabolism in Drug Design and Development and Mass Spectrometry in Drug Metabolism and Disposition and co-authored 100+ research articles (https://pubmed.ncbi.nlm.nih.gov/?term=Mingshe%20Zhu&sort=date).